SPARC (Osteonectin) in breast tumors of different histologic types and its role in the outcome of invasive ductal carcinoma

Breast Journal

Volumn 16, Issue 3, 2010, Pages 305-308

  Hsiao, Yi Hsuan ^a,b,c   Lien, Huang Chun ^d   Hwa, Hsiao Lin ^d   Kuo, Wen Hung ^d   Chang, King Jen ^d   Hsieh, Fon Jou ^d  

^a CHUNG SHAN MEDICAL UNIVERSITY   (Taiwan)

^b CHANG JUNG CHRISTIAN UNIVERSITY   (Taiwan)

^c CHANGHUA CHRISTIAN HOSPITAL   (Taiwan)

^d NATIONAL TAIWAN UNIVERSITY   (Taiwan)

Author keywords

Breast tumor; Immunohistochemistry; Secreted protein acidic and rich in cystein

Indexed keywords

ESTROGEN RECEPTOR; OSTEONECTIN; PROGESTERONE RECEPTOR;

ARTICLE; BENIGN TUMOR; BREAST CARCINOMA; BREAST METAPLASTIC CARCINOMA; BREAST TUMOR; CANCER PATIENT; CANCER STAGING; CONTROLLED STUDY; CYSTOSARCOMA PHYLLOIDES; DISEASE ASSOCIATION; HISTOPATHOLOGY; HUMAN; IMMUNOHISTOCHEMISTRY; INVASIVE DUCTAL CARCINOMA; MAJOR CLINICAL STUDY; MALIGNANT NEOPLASTIC DISEASE; OVERALL SURVIVAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN LOCALIZATION; PROTEIN SECRETION; SURVIVAL TIME; TUMOR CLASSIFICATION; CHEMISTRY; FEMALE; MORTALITY; PAGET NIPPLE DISEASE; PATHOLOGY; PHYSIOLOGY; PROPORTIONAL HAZARDS MODEL;

BREAST NEOPLASMS; CARCINOMA, DUCTAL, BREAST; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; NEOPLASM STAGING; OSTEONECTIN; PROPORTIONAL HAZARDS MODELS;

EID: 77953549226     PISSN: 1075122X     EISSN: 15244741     Source Type: Journal    
DOI: 10.1111/j.1524-4741.2009.00899.x     Document Type: Article

References (10)

1. Campo McKnight DA, Sosnoski DM, Koblinski JE, Gay CV. Roles of osteonectin in the migration of breast cancer cells into bone. J Cell Biochem 2006;97:288-302.
2. Barth PJ, Moll R, Ramaswamy A. Stromal remodeling and SPARC (secreted protein acid rich in cysteine) expression in invasive ductal carcinomas of the breast. Virchows Arch 2005;446:532-536
3. Lien HC, Hsiao YH, Lin YS, et al. Molecular signatures of metaplastic carcinoma of the breast by large-scale transcriptional profiling:identification of genes potentially related to epithelial-mesenchymal transition. Oncogene 2007;26:7859-7871
4. Kato Y, Nagashima Y, Baba Y, et al. Expression of SPARC in tongue carcinoma of stage II is associated with poor prognosis: an immunohistochemical study of 86 cases. Int J Mol Med 2005;16:263-268
5. Yamashita K, Upadhay S, Mimori K, Inoue H, Mori M. Clinical significance of secreted protein acidic and rich in cystein in esophageal carcinoma and its relation to carcinoma progression. Cancer 2003;97:2412-2419
6. Yamanaka M, Kanda K, Li NC, et al. Analysis of the gene expression of SPARC and its prognostic value for bladder cancer. J Urol 2001;166:2495-2499
7. Massi D, Franchi A, Borgognoni L, Reali UM, Santucci M. Osteonectin expression correlates with clinical outcome in thin cutaneous malignant melanomas. Hum Pathol 1999;30:339-344
8. Wang CS, Lin KH, Chen SL, Chan YF, Hsueh S. Overexpression of SPARC gene in human gastric carcinoma and its clinic-pathologic significance. Br J Cancer 2004;91:1924-1930
9. Said N, Najwer I, Motamed K. Secreted protein acidic and rich in cysteine (SPARC) inhibits integrin-mediated adhesion and growth factor-dependent survival signaling in ovarian cancer. Am J Pathol 2007;170:1054-1063
10. Infante JR, Matsubayashi H, Sato N, et al. Peritumoral fibroblast SPARC expression and patient outcome with resectable pancreatic adenocarcinoma. J Clin Oncol 2007;25:319-325